Failure to engraft after hematopoietic stem cell transplantation (graft dysfunction) or to sustain engraftment (graft rejection) is a formidable complication due to many possible factors. These include inadequate stem cell numbers, infections, graft-versus-host disease and immunological mediated processes. Fortunately, this complication is uncommon and can be overcome by additional hematopoietic stem cell infusions. Multiple treatment alternatives have been explored including hematopoietic growth factors, additional infusions of stem cells alone, with augmented immunosuppression or with additional cytotoxic therapy. Various sources of the additional stem cells are feasible including the original donor, using another donor, using stem cells collected from the marrow or after cytokine mobilization from the peripheral blood. This report will overview this complication and review the various studies that have attempted to define both cause and therapy. However, a lack of well-designed prospective studies has made definitive recommendations difficult although basic principles have been established. Bone Marrow Transplantation (2002) 29, 545-552. DOI: 10.1038/sj/bmt/1703389 Keywords: graft failure; graft rejection; second HSC transplant For the most part, two circumstances after allogeneic transplantation necessitate consideration for a second hematopoietic stem cell (HSC) transplant: (1) graft failure or rejection (dysfunction) and (2) disease relapse without graft dysfunction. This review will focus on the transplantation of substantial numbers of HSCs after a first allogeneic HSC transplant in order to augment graft function or the performance of a second transplant (including cytotoxic therapy) for disease relapse.
further characterized as hematopoietic (myeloid) or lymphoid, determined by increasingly sophisticated technology able to identify exceedingly small cell populations. 1 On a practical basis, engraftment is defined as the first day of achieving a sustained peripheral blood neutrophil count Ͼ500 ϫ 10 6 /l. Similarly, graft failure is the inability to sustain donor cell engraftment, and rejection, sometimes called secondary graft failure, is the substantial diminution of donor cells after successful engraftment.
Graft dysfunction
Failure to engraft after marrow ablative therapy is lifethreatening but fortunately occurs at an overall frequency of less than 5%. [2] [3] [4] Graft failure may be due to an inadequate numbers of transplanted HSC or to the failure of adequate number of cells to survive. The barriers to engraftment include immunologic destruction, infectious agents, drug toxicity or a poor marrow microenvironment. 5 
Factors influencing graft dysfunction
In autologous transplantation, the dose of HSC measured as CD34
ϩ cells relates to the rapidity of engraftment best demonstrated with peripheral stem cell dosing. [6] [7] [8] For allogeneic transplantation, the dose of HSC is crucial to engraftment best demonstrated in patients with severe aplastic anemia (sAA), conditioned with cyclophosphamide, where a dose of Ͼ3 ϫ 10 8 /kg nucleated cells increased the likelihood of engraftment. 9 In this early series, optimal immunosuppression was not achieved since most patients received only methotrexate for graft-versus-host disease (GVHD) prophylaxis and additional donor lymphocyte (buffy coat) infusions facilitated sustained engraftment unfortunately with an increase in chronic GVHD. An update of this Seattle experience reviewed 333 patients with sAA transplanted between 1970 and 1996. 10 Reflecting the changing process of transplantation practices, the rate of rejection decreased from 35% in the period of [1970] [1971] [1972] [1973] [1974] [1975] [1976] , to 12% in the period of 1977-1981 (P Ͻ 0.001) and ultimately to 9% in the period of [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] [1995] [1996] . The onset of graft dysfunction was also delayed in the latter period with a median onset of 180 days (range . Twelve patients in the period of 1982-1996 received a second transplant prepared with the addition of ATG to cyclophosphamide conditioning and cyclosporine to methotrexate for GVHD prophylaxis. These patients demonstrated a reduced rejection rate of 25% and excellent survival. Other series of sAA patients using more profound cytotoxic therapy (eg TBI) and effective GVHD prophylaxis (cyclosporine) have demonstrated significant reduction of graft dysfunction with an estimated frequency of approximately 10%. 11, 12 However, sAA may not be the best measure for graft failure since it is itself graft dysfunction and frequently immune mediated. Supporting this observation is the reduced rejection rate (4.0%) observed after transplantation for hepatitis-induced sAA, a disorder felt not to be immunologically based. 12 Furthermore, graft dysfunction is more problematic in diseases such as sickle cell anemia and thalassemia since patients are extensively transfused without chronic immunologic suppression caused by previous cytotoxic therapy. 13 Graft dysfunction is more common with disparate donor (eg haplo-identical related, unrelated marrow and umbilical cord) transplants, after T cell-depleted marrow transplants or with reduced intensity preparative regimens. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] In unrelated marrow transplants HLA class II disparity may not affect graft dysfunction while class I disparity, especially HLA-C, was associated with graft dysfunction. [27] [28] [29] [30] [31] Other reports suggest that residual recipient NK cells can mediate graft dysfunction. [32] [33] [34] Aside from disease or immunologic mechanisms of graft dysfunction, the compromised marrow microenvironment of heavily pre-treated recipients or the occurrence of CMV, HHV 6 and HHV 8 infections have been implicated in causing graft failure. [35] [36] [37] [38] Although graft rejection usually occurs within the first 6 months after transplantation, very late graft rejection has been reported in sAA, even with intense conditioning. 39 Rejection may be heralded by incomplete and decreasing donor chimerism, allowing the re-expression of host T cell function. [40] [41] [42] [43] Graft dysfunction is an ominous circumstance and may herald relapse of neoplasm with restoration of host hematopoiesis.
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Management of graft dysfunction
Whatever the etiology, the occurrence of graft failure or rejection should be identified early and recognized as a serious and life-threatening process requiring intervention. Management has consisted of augmentation by growth factors without additional HSC infusions, infusions of HSC without additional cytotoxic therapy (boost) or the performance of a complete second transplant with pre-infusion conditioning.
Use of growth factors to enhance hematopoiesis after graft dysfunction
Some patients, especially those with HLA disparate or ABO mis-matched transplants, may manifest slow engraftment and transient periods of dysfunction commonly associated with GVHD. 47 Early reports of cytokine support for graft dysfunction used GM-CSF after allogeneic transplantation with varying results. 48, 49 Many patients respond to cytokines with an increase in absolute neutrophil count with some responders maintaining counts after discontinuation of GM-CSF. The best results are noted in patients having at least partial donor hematopoietic chimerism or receiving a second HSC infusion. The combination of GM-CSF followed by G-CSF was compared to GM-CSF alone in patients with graft failure or rejection after related or unrelated allogeneic transplantation. 50 More than 85% of patients responded, within a median of 9 days, with an increase of neutrophils to Ͼ500 ϫ 10 6 /l. As anticipated by the lineage specificity of these cytokines, salutary effect on red blood cell and platelet recovery was not noted. In this series, the 100 day survival after cytokine therapy was substantial (Ͼ70%) and statistically improved in those patients receiving only GM-CSF. Nonetheless, the role for the commercially available growth factors to abrogate graft dysfunction after allogeneic transplantation is still not clear. Certainly, hematopoietic growth factors should be considered an adjunct in the management of graft dysfunction, especially with partial donor chimerism. A primary role for hematopoietic growth factors has not been established.
The effect of HSC dose on graft dysfunction
Augmentation of HSC dose has been assumed to reduce the likelihood of graft dysfunction since 'inadequate' dose is related to the occurrence of graft dysfunction. 51 Supporting this hypothesis is 'mega-dose' HSC infusion as a successful measure to avoid rejection of T cell-depleted haploidentical peripheral blood stem cell transplantation. 52 In this study, 41 of 43 patients initially engrafted after receiving large doses of peripheral blood HSC and those with graft dysfunction underwent successful second HSC transplants from a different donor. The ideal HSC dose to help prevent dysfunction has not been established although this study administered a mean of Ͼ10 ϫ 10 6 /kg of CD34 ϩ cells. In addition to a dose-effect, high-dose HSC infusions may also modulate graft dysfunction by infusing 'veto' cells which inhibit host alloreactivity. Such cells are located in various cells populations including CD34 ϩ , NK, CD2 ϩ , CD8 ϩ and dendritic cell populations. [53] [54] [55] [56] [57] [58] [59] Increasing dose may not necessarily be associated with increased benefit as noted in one retrospective series suggesting poorer survival with increasing HSC dose in matched related T cell-deplete allogeneic transplants. 60 
Second HSC transplantation for graft dysfunction
There are many reports of second HSC transplants for graft dysfunction. Unfortunately, clinical and treatment heterogeneity, including additional conditioning and immunosuppression, the source of HSC, or the use of a different donor make global conclusions difficult. Nonetheless, the performance of a second HSC infusion offers survival potential as demonstrated in patients with sAA after graft dysfunction where few survive long-term without additional HSC engraftment.
A retrospective multicenter review from the Société Française de Greffe de Moelle (SFGM) analyzed 82 second early allogeneic HSC transplants for graft dysfunction in patients treated between 1985 and 1997 for acute leukemia, chronic myeloid leukemia or sAA. 61 Approximately onethird of the patients had graft failure with the remainder graft rejection. The median time from first to second transplant was 62 days (range 32-307), 46 days (range 32-116) for graft failure and 84 days (range 34-307) for graft rejection. Conditioning for the second transplant consisted of cytotoxic therapy in most patients although 13 received only anti-T cell serotherapy. The same donor was used in 68% of second transplants and 20 patients received additional hematopoietic growth factors. Overall, neutrophil recovery was 73% with peripheral blood, as the HSC source, associated with a more rapid recovery. The probability of grades II-IV and III-IV GVHD was 41% and 17%, respectively. Estimates of the 3-year overall survival and day 100 transplant-related mortality were 30% and 53%, respectively. Recipient age Ͻ34 years, an intertransplant time of Ͼ80 days, the use of cyclosporine alone for GVHD prophylaxis and positive recipient CMV serology were predictors of a better outcome. Twelve percent of successfully engrafted patients developed second graft dysfunction and one of five patients receiving a third transplant survived more than 3 years.
The evidence for not needing additional cytotoxic therapy was raised in a report of 20 patients (4% of all transplanted patients) who received a second HSC infusion for failure to establish stable engraftment (leukocytes or platelets), graft rejection or the persistence of donor immune cells causing hemolysis. 62 No additional chemotherapy or radiation conditioning was administered although four patients received ATG. HSC sources included marrow and peripheral blood mobilized cells. Except for one patient, GVHD after the second HSC infusion was not substantial. Fifteen patients showed an improvement of neutrophil count to Ͼ500 ϫ 10 6 /l or became platelet transfusion independent. Overall survival after HSC boost was 43% at 3 years with better outcome after graft rejection and after related marrow transplantation. The heterogeneity of this patient population makes firm conclusions difficult but suggests that boost HSC can be effective after graft rejection.
Second marrow HSC transplants from unrelated donors were described in 12 patients with graft dysfunction. 63 For primary transplantation, patients received T cell-depleted marrow (median cell dose of 5.6 ϫ 10 8 /kg) matched at the molecular level (HLA-A, -B, -DR and -DQ) for two-thirds of patients with the remainder one allelic mis-matched (three class I and one class II). Anti-T cell serotherapy was given to all patients followed by aggressive cytotoxic conditioning and cyclosporine GVHD prophylaxis. The median time from the first to the second HSC infusion was 5 months (range 1-13) with five infusions from the original and seven from another donor. The degree of disparity was not improved for patients receiving a second infusion from a different donor (median cell dose 5.7 ϫ 10 8 /kg). The additional cytotoxic conditioning was generally less intense compared to the primary transplant; no second infusion was T cell depleted, although most patients received anti-T cell serotherapy. Nine of 10 evaluable patients engrafted at a median time of 17 days (range 12-39); one patient failed to engraft and one rejected the second infusion. GVHD occurred in a total of nine patients and was severe in three. Five patients survive at 21-66 months after the second infusion although not all remain free of their primary malignant disease.
Bone Marrow Transplantation
The source of HSC for second transplants
The best HSC source remains unclear although higher cell doses are achieved with the use of cytokine-mobilized peripheral blood HSC infusion. Two children with sAA and sickle cell anemia after graft rejection were successfully treated with additional cytotoxic therapy, cyclosporine GVHD prophylaxis and G-CSF-mobilized HSC. 64 Two adults with AML who experienced graft failure were successfully engrafted after unsuccessful G-CSF treatment using a second HSC transplant with ATG conditioning. 65 HSC were obtained from a different donor in one patient and the same donor in the other. Another report used G-CSF-mobilized peripheral stem cells with lymphocytes for persistence of substantial recipient isohemagglutinins 6 months after first marrow HSC infusion. 66 The HSC enhanced DLI suppressed residual recipient cells and reduced host immunologic reactivity against donor cells resulting in improved erythropoiesis.
Second HSC transplantation for relapse
Disease relapse is an ominous occurrence after allogeneic HSC transplantation. Results are poor with cytotoxic therapy alone and second HSC transplants have been associated with substantial regimen-related toxicity (RRT). [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] Summaries have been published from many large cooperative groups demonstrating reasonable long-term survival although with substantial risk of treatment-related mortality (TRM). One case report of DLI failure demonstrated subsequent salvage by another full transplant. 81 Notwithstanding this case, the relative merit of DLI compared to a full second transplant has not been adequately studied and will relate to many factors especially diagnosis and stage of disease.
General outcome for relapse
The International Blood and Marrow Transplant Registry (IBMTR) reported 145 second HSC transplants from 1978 to 1989; 114 were HLA-matched siblings and the remainder from a variety of donors with all patients receiving cytotoxic conditioning prior to the second infusion. 82 After the second infusion, GVHD, hepatic veno-occlusive disease (VOD), and pulmonary interstitial pneumonia increased with a 2-year probability of TRM of 41%. The risk of TRM was 3.9 times greater in patients receiving a second HSC within 6 months of the first HSC infusion. The 2-year probability of relapse after the second transplant was 65% and more frequent in patients not having achieved remission from the first transplant. The 2-year probability of leukemia-free survival (LFS) was 21% -best with a diagnosis of CML, acute leukemia in remission, initial remission greater than 6 months and increased performance status.
The Gruppo Italiano Trapianto di Midolo Osseo (GITMO) reported their experience with second HSC transplants from 1987 to 1994. 83 Thirty-eight patients (median age 19 years with range 2-46) had ALL or AML in relapse or remission induced by additional cytotoxic treatment. The second HSC transplant was performed at a median time of 13 months (range 4-88) after the first HSC transplant. All received second transplants from a genotypic HLA-identical sibling (four not being the original donor) with intensive conditioning determined by the prior administration of TBI. GVHD prophylaxis was given to most patients. Prompt hematopoietic recovery occurred in all evaluable patients resulting in a 3-year probability of event-free survival (EFS) of 42%, improved for AML compared to ALL but not improved in remission compared to relapse. Early TRM was 18.4% with a 3-year probability of 28%. Acute GVHD increased after the second HSC transplant and was noted in 15 of 25 patients who apparently did not develop GVHD after the first transplant.
The SFGM reviewed 6709 allogeneic HSC transplant patients from 1984 to 1996 and noted 150 who underwent second HSC for relapse of acute or chronic leukemia. 84 Their median age was 25 years (range 1.5-46) with 107 adults and 43 children. Diagnoses consisted of AML (n = 61), ALL (n = 47) or CML (n = 42); most patients were in complete remission or in chronic phase (for CML) at the time of the initial transplant. At the time of the second transplant, a variety of treatments were undertaken with all patients receiving cytotoxic conditioning, 83% having the same donor, 20% receiving no GVHD prophylaxis, 7% receiving mobilized peripheral blood HSC, 2% receiving T cell-depleted HSC and two syngeneic patients receiving a second allogeneic HSC infusion. Engraftment occurred in 93% of patients, 57% developed GVHD grade II-IV, 23% had severe grade III-IV GVHD and 38% developed chronic GVHD. With a median follow-up of 30 months, 24% of patients relapsed and 68% died of TRM resulting in an overall 5-year disease-free survival (DFS) of 30%. In multi-variate analysis, five factors correlated with improved survival (overall and disease-free): age Ͻ16 years, relapse Ͼ1 year after the first transplant, absence of acute GVHD, occurrence of chronic GVHD and the use of a female donor. Statistical limitations prevented analysis of the impact of the state of disease prior to second transplantation.
The Seattle group reported their results of second HSC transplantation for recurrent leukemia (CML, AML and ALL) after initial transplantation with a TBI-containing regimen. 85 Despite treatment at a single institution, second treatment varied reflecting the clinical practice at the time of the second transplant. The median time from first to second transplant was 28 months (range 3-187), all patients used the same donor, had evidence of prior lymphoid engraftment and received cytotoxic chemotherapy conditioning regimens. GVHD prophylaxis consisted of varying combinations of T cell depletion, immunosuppressive agents and anti-T cell serotherapy. Sustained engraftment occurred in all evaluable patients. Severe RRT occurred in 39% reflecting a greater than four-fold increase compared to the initial transplant; 62% of all patients developed VOD. At 1 year after second transplantation, non-relapse-related mortality was 45% and relapse was 70% resulting in an overall DFS probability of 14%, slightly improved for CML patients (28%). Severe VOD, age Ͼ10 years and GVHD Ͼ grade II adversely affected DFS.
Comparison of autologous vs allogeneic second HSC transplant
The decision to perform a second transplant using autologous or allogeneic HSC was discussed by the European Cooperative Group for Blood and Marrow Transplantation (EBMT) with a review of 2752 patients (1981-1997) who relapsed after undergoing primary autologous HSC for AML in remission. 86 Ninety-four and 74 patients, respectively, underwent allogeneic or autologous second HSC transplant. TRM at 2 years was 51% in recipients of matched allografts and 26% following an autograft (P Ͻ 0.05). Two-year DFS was 27% and 35% in the two groups, respectively (P = NS). TRM was increased in patients who were in second or later remission at the time of the initial autograft (P Ͻ 0.05) and recipients of a second allograft (P Ͻ 0.05). Relapse was more common in patients with ALL (P Ͻ 0.001), patients Ͼ25 years of age (P Ͻ 0.02), first autografts performed later than 1991 (P Ͻ 0.05), and with second autografts (P Ͻ 0.05). LFS was decreased in patients Ͻ25 years of age (P Ͻ 0.01), if the interval from first autograft to relapse was 8 months or less (P Ͻ 0.01) and if TBI was used at first autograft (P Ͻ 0.05). Reviews like this indicate that second HSC should be considered without defining whether the outcome will be affected by the choice of an allogeneic or autologous source of cells or whether allogeneic peripheral blood HSC will reduce TRM and thus increase overall long-term survival.
The source of HSC for second HSC transplant
The outcome using mobilized peripheral blood allogeneic HSC for second transplant was described in 10 patients after receiving an initial marrow HSC transplant. 87 Substantial heterogeneity of the small group was noted although hematopoietic recovery was more rapid by approximately 1 week after the second HSC transplant. Other studies confirm that G-CSFmobilized stem cells result in rapid engraftment similar to primary transplantation. [88] [89] [90] The overall benefit of peripheral compared to marrow cells has not been established by longterm data although the former will invariably result in a larger cell dose, more rapid engraftment and reduced early morbidity, albeit with the possibility of increased chronic GVHD.
Cost-effectiveness for second HSC transplant
Cost analysis of a second HSC transplant compared to conventional (non-transplant) options was performed in a retrospective study. 91 Data were derived from patients with acute leukemia who failed a first allogeneic HSC transplant. Patients from five second HSC transplant series (n = 167) and two non-transplant series (n = 299) were analyzed with outcome derived using survival extrapolation. Improved long-term (P Ͻ 0.001) and median survival (P Ͻ 0.001)) of 20% and 10 months compared to 0% and 3 months was noted for the HSC transplant group and conventional therapy group, respectively. The estimated cost was $150 000 for HSC transplantation (range $90 000 to $200 000) and $60 000 for conventional treatment. The analysis noted a cost benefit for HSC transplantation of $52 215 per life year gained extrapolated from a survival gain of 19.6 discounted months for the transplant group. Although substantial, this magnitude of cost was judged reasonable and justifiable in comparison with other oncologic interventions, especially considering the observation of long-term EFS.
Decision analysis for a second HSC transplant
The occurrence of severe graft dysfunction or malignant disease relapse is an indication for consideration of a second HSC transplant. In any case, hematopoietic growth factors should be utilized, especially with evidence of partial donor chimerism. The persistence of host cells, even without graft dysfunction, is a harbinger of disease relapse and warrants similar consideration; although DLI (without HSC infusion) may be an alternative, prospective comparisons with full transplants have not been performed.
An evaluation for the cause of graft dysfunction should be instituted to determine whether the patient received an ample HSC infusion together with sufficient immunosuppression to blunt the likelihood of residual host immunity (Table 1) . If a cause of graft dysfunction is noted, then specific modifications for the second HSC transplant should be undertaken. If no cause is determined, then an immunologic mechanism must be considered and the second transplant should be undertaken with augmented immunosuppressive measures.
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Guidelines for a second HSC transplant
Despite the lack of prospective randomized trials, there are basic tenets for a second HSC transplant, although there remain many unanswered questions that make absolute recommendations difficult. Some basic guidelines include:
1 Graft failure (absence of donor chimerism) without specific cause, especially with an adequate number of infused HSC, suggests a potent host immunologic mechanism of graft dysfunction. In this case, the second HSC transplant should be performed with enhanced immunosuppression including consideration for additional cyto- 
Remaining questions for second HSC
Despite many years of clinical evaluations for second HSC transplantation, many issues remain unresolved. Some of these will remain so unless a uniform method for second transplants is considered. Issues still unresolved include the following:
1 When should a different donor be used? 2 Should HSC infusion without additional cytotoxic therapy (boost) ever be used or should all second HSC infusions be performed with additional immunosuppressive treatment? 3 With partial donor chimerism, is anti-T cell serotherapy followed by HSC infusion adequate for graft dysfunction or should additional cytotoxic immunosuppression be added? 4 What role does DLI have in ameliorating residual partial host chimerism to improve graft function? 5 What is the role of DLI compared to a second HSC transplant for the treatment of disease relapse?
With fastidious management of the patient having graft dysfunction, this once formidable complication can be overcome with a second HSC infusion. However, graft dysfunction is still an adverse event reducing overall survival. The prognosis for long-term survival is improved with graft dysfunction occurring well after initial infusion and with evidence of partial donor chimerism. Second HSC transplantation for graft dysfunction should be considered a standard of practice. The relapse of malignant disease can also be overcome with a complete second HSC transplant although results are still unsatisfactory compared to first transplants and additional alternatives require careful investigation.
